Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 26 articles:
HTML format
Text format



Single Articles


    September 2017
  1. VENEMA CM, Mammatas LH, Schroder CP, van Kruchten M, et al
    Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies.
    J Nucl Med. 2017 Sep 14. pii: jnumed.117.193649. doi: 10.2967/jnumed.117.193649.
    PubMed     Text format     Abstract available


    August 2017
  2. HENRY KE, Dilling TR, Abdel-Atti D, Edwards KJ, et al
    Non-invasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared to 18F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer.
    J Nucl Med. 2017 Aug 28. pii: jnumed.117.192286. doi: 10.2967/jnumed.117.192286.
    PubMed     Text format     Abstract available


  3. PAQUETTE M, Lavallee E, Phoenix S, Ouellet R, et al
    Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 4FMFES in ER+ Breast Cancer Patients: an Ongoing Phase II Clinical Trial.
    J Nucl Med. 2017 Aug 10. pii: jnumed.117.194654. doi: 10.2967/jnumed.117.194654.
    PubMed     Text format     Abstract available


    June 2017
  4. MORTIMER JE, Bading JR, Park JM, Frankel PH, et al
    Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.193888. doi: 10.2967/jnumed.117.193888.
    PubMed     Text format     Abstract available


    April 2017
  5. AHRENS BJ, Li L, Ciminera AK, Chea J, et al
    Diagnostic PET Imaging of Mammary Microcalcifications using 64Cu-DOTA-alendronate in a Rat Model of Breast Cancer.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.190850. doi: 10.2967/jnumed.117.190850.
    PubMed     Text format     Abstract available


  6. DALM SU, Haeck J, Doeswijk GN, de Blois E, et al
    SSTR-mediated Breast Cancer Imaging: Is There A Role For Radiolabeled SSTR Antagonists?
    J Nucl Med. 2017 Apr 27. pii: jnumed.116.189035. doi: 10.2967/jnumed.116.189035.
    PubMed     Text format     Abstract available


  7. DONOHOE KJ, Cohen EJ, Giammarile F, Grady E, et al
    Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts.
    J Nucl Med. 2017;58:14N-17N.
    PubMed     Text format    


  8. GROHEUX D
    18F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer.
    J Nucl Med. 2017;58:683.
    PubMed     Text format    


    March 2017
  9. MORGAT C, MacGrogan G, Brouste V, Velasco V, et al
    Expression of Gastrin-Releasing Peptide Receptor (GRPR) in Breast Cancer and its Association with Pathological, Biological and Clinical Parameters: A Study of 1432 Primary Tumors.
    J Nucl Med. 2017 Mar 9. pii: jnumed.116.188011. doi: 10.2967/jnumed.116.188011.
    PubMed     Text format     Abstract available


    January 2017
  10. LI L, Wu Y, Wang Z, Jia B, et al
    SPECT/CT Imaging of the Novel HER2-targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models.
    J Nucl Med. 2017 Jan 19. pii: jnumed.116.183863. doi: 10.2967/jnumed.116.183863.
    PubMed     Text format     Abstract available


    December 2016
  11. CHAE SY, Kim SB, Ahn SH, Moon DH, et al
    Reply: 18F-fluoroestradiol positron emission tomography to predict response to neoadjuvant treatment in luminal breast cancer.
    J Nucl Med. 2016 Dec 8. pii: jnumed.116.185660.
    PubMed     Text format    


    November 2016
  12. FOWLER AM, Linden HM
    Functional Estrogen Receptor Imaging Prior to Neoadjuvant therapy for Primary Breast Cancer.
    J Nucl Med. 2016 Nov 17. pii: jnumed.116.183533.
    PubMed     Text format    


    October 2016
  13. YANG H, Jenni S, Colovic M, Merkens H, et al
    18F-5-fluoro-aminosuberic acid (FASu) as a potential tracer to gauge oxidative stress in breast cancer models.
    J Nucl Med. 2016 Oct 27. pii: jnumed.116.180661.
    PubMed     Text format     Abstract available


    September 2016
  14. CHAE SY, Kim SB, Ahn SH, Kim HO, et al
    A randomized feasibility study of 18F-fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer.
    J Nucl Med. 2016 Sep 29. pii: jnumed.116.178368.
    PubMed     Text format     Abstract available


  15. LEBON V, Alberini JL, Pierga JY, Dieras V, et al
    The rate of distant metastases on FDG-PET/CT at initial staging of breast cancer: comparison between women younger and older than 40 years.
    J Nucl Med. 2016 Sep 1. pii: jnumed.116.178749.
    PubMed     Text format     Abstract available


    June 2016
  16. DOOT RK
    Invited Perspective for: 18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.175687.
    PubMed     Text format    


    May 2016
  17. MCCONATHY J
    [F-18]Fluciclovine (FACBC) and its Potential Use for Breast Cancer Imaging.
    J Nucl Med. 2016 May 19. pii: jnumed.116.175489.
    PubMed     Text format    


  18. LIN CY, Lin CL, Kao CH
    Reply: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 19. pii: jnumed.116.178152.
    PubMed     Text format    


  19. ULANER GA, Hyman D, Ross D, Corben A, et al
    Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using the 89Zr-DFO-trastuzumab PET/CT.
    J Nucl Med. 2016 May 5. pii: jnumed.115.172031.
    PubMed     Text format     Abstract available


  20. CHEN KT, Hu YW
    Letter: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 5. pii: jnumed.116.173641.
    PubMed     Text format    


    February 2016
  21. VAN ES SC, Venema CM, Glaudemans AW, Lub-de Hooge MN, et al
    Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.
    J Nucl Med. 2016;57 Suppl 1:96S-104S.
    PubMed     Text format     Abstract available


  22. GEBHART G, Flamen P, De Vries EG, Jhaveri K, et al
    Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.
    J Nucl Med. 2016;57 Suppl 1:81S-8S.
    PubMed     Text format     Abstract available


  23. BERG WA
    Nuclear Breast Imaging: Clinical Results and Future Directions.
    J Nucl Med. 2016;57 Suppl 1:46S-52S.
    PubMed     Text format     Abstract available


  24. HSU DF, Freese DL, Levin CS
    Breast-Dedicated Radionuclide Imaging Systems.
    J Nucl Med. 2016;57 Suppl 1:40S-5S.
    PubMed     Text format     Abstract available


  25. WAHL RL
    Quo Vadis: PET and Single-Photon Molecular Breast Imaging.
    J Nucl Med. 2016;57 Suppl 1:3S-8S.
    PubMed     Text format    


  26. CZERNIN J, Mankoff D
    Introduction and Overview.
    J Nucl Med. 2016;57 Suppl 1:1S-2S.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: